Radioiodine labeled anti-MIF McAb: A potential agent for inflammation imaging

Mediators of Inflammation

Volumn 2007, Issue , 2007, Pages

  Zhang, Chao ^a,b   Hou, Gui Hua ^b   Han, Jian Kui ^a   Song, Jing ^b   Liang, Ting ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY MACROPHAGE INHIBITORY FACTOR IODINE 125; SODIUM IODIDE I 125; TRACER; TURPENTINE OIL; UNCLASSIFIED DRUG; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; TURPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG BINDING; DRUG DISTRIBUTION; ENTEROBACTER INFECTION; ESCHERICHIA COLI; IN VIVO STUDY; INFLAMMATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; AUTORADIOGRAPHY; BACTERIAL INFECTION; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

ANIMALIA; MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; IODINE RADIOISOTOPES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION; TURPENTINE; WHOLE-BODY COUNTING;

EID: 36248939675     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2007/50180     Document Type: Article

References (25)

1. B. R. Bloom B. Bennett Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 3731 1966 80 82
2. J. R. David Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences of the United States of America 56 1 1966 72 77
3. J. Bernhagen T. Calandra R. A. Mitchell MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365 6448 1993 756 759
4. C. M. Denkinger C. Metz G. Fingerle-Rowson M. D. Denkinger T. G. Forsthuber tgf2@cwru.edu Macrophage migration inhibitory factor and its role in autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis 52 6 2004 389 400
5. T. Calandra Thierry.Calandra@hospvd.ch T. Roger Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Reviews Immunology 3 10 2003 791 800
6. E. Lolis elias.lolis@yale.edu Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Current Opinion in Pharmacology 1 6 2001 662 668
7. Y. P. De Jong A. C. Abadia-Molina A. R. Satoskar Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology 2 11 2001 1061 1066
8. F. A. Bozza R. N. Gomes A. M. Japiassú Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22 4 2004 309 313
9. T. Ohkawara J. Nishihira H. Takeda Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123 1 2002 256 270
10. Y. Sakai A. Masamune amasamune@int3.med.tohoku.ac.jp A. Satoh J. Nishihira T. Yamagiwa T. Shimosegawa Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 124 3 2003 725 736
11. M. Leech C. Metz P. Hall Macrophage migration inhibitory factor in rheumatoid arthritis:evidence of proinflammatory function and regulation by glucocorticoids. Arthritis and Rheumatism 42 8 1999 1601 1608
12. N. Yabunaka noriyabu@med.hokudai.ac.jp J. Nishihira Y. Mizue Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 23 2 2000 256 258
13. F. Nicoletti A. Créange creange@univ-paris12.fr D. Orlikowski Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis. Journal of Neuroimmunology 168 1-2 2005 168 174
14. M. Niino niino@med.hokudai.ac.jp A. Ogata S. Kikuchi K. Tashiro J. Nishihira Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease. Journal of the Neurological Sciences 179 1-2 2000 127 131
15. C. J. van der Laken O. C. Boerman W. J. G. Oyen M. T. P. van de Ven J. W. M. van der Meer F. H. M. Corstens Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. European Journal of Nuclear Medicine 25 5 1998 535 546
16. W. Becker The contribution of nuclear medicine to the patient with infection. European Journal of Nuclear Medicine 22 10 1995 1195 1211
17. S. Vinjamuri A. V. Hall K. K. Solanki Comparison of T 99 m c infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 347 8996 1996 233 235
18. E. P. Krenning D. J. Kwekkebomm S. Pauwels L. K. Kvols J. C. Reubi Somatostatin receptor scintigraphy. Nuclear Medicine Annual Raven Press New York, NY, USA 1995 1 50
19. M. R. Plucher P. J. Blower Labelling of lekocytes with colloidal tecnetium-99m-Sn F 2: an investigation of the labeling process by autoradiography. European Journal of Nuclear Medicine and Molecular Imaging 22 2 1995 101 107
20. G. Ferro-Flores gff@nuclear.inin.mx C. Arteaga de Murphy M. Pedraza-López In vitro and in vivo assessment of T 99 m c -UBI specificity for bacteria. Nuclear Medicine and Biology 30 6 2003 597 603
21. G. W. Visser R. P. Klok J. W. K. Gebbinck T. Ter Linden G. A. van Dongen C. F. Molthoff Optimal quality I 131 -monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. Journal of Nuclear Medicine 42 3 2001 509 519
22. G. C. Jayson J. Zweit A. Jackson Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody:implications for trial design of antiangiogenic antibodies. Journal of the National Cancer Institute 94 19 2002 1484 1493
23. I. Verel G. W. M. Visser R. Boellaard Quantitative Z 89 r immuno-PET for in vivo scouting of Y 90 -labeled monoclonal antibodies in xenograft-bearing nude mice. Journal of Nuclear Medicine 44 10 2003 1663 1670
24. E. F. Morand enc.morand@med.monash.edit.au New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Internal Medicine Journal 35 7 2005 419 426
25. D. Aeberli M. Leech E. F. Morand eric.morand@med.monash.edu.au Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology 45 8 2006 937 943